再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

盘前交易 09-29 09:11:16 EDT

752.25

-35.79

-4.54%

盘前752.00

-0.25-0.03%

09:06 EDT

最高780.95	最低750.00	成交量114.98万
今开778.09	昨收788.04	日振幅3.93%
总市值774.48亿	流通市值743.85亿	总股本1.03亿
成交额8.70亿	换手率1.16%	流通股本9,888万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":752.25,"timestamp":1790625600000,"preClose":788.04,"halted":0,"volume":1149832,"hourTrading":{"tag":"盘前","latestPrice":752,"preClose":752.25,"latestTime":"09:06 EDT","volume":84,"amount":63002.36376,"timestamp":1790687162139,"change":-0.25,"changeRate":-0.000332,"amplitude":0.034862},"delay":0,"changeRate":-0.04541647632099889,"floatShares":98883600,"shares":102954988,"eps":40.43335,"marketStatus":"盘前交易","change":-35.79,"latestTime":"09-29 09:11:16 EDT","open":778.09,"high":780.945,"low":750,"amount":870069135.6768,"amplitude":0.039268,"askPrice":759,"askSize":16,"bidPrice":737.21,"bidSize":10,"shortable":3,"etf":0,"ttmEps":40.43335,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790688600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":752.25,"dividendRate":0.004839,"preHourTrading":{"tag":"盘前","latestPrice":752,"preClose":752.25,"latestTime":"09:06 EDT","volume":84,"amount":63002.36376,"timestamp":1790687162139,"change":-0.25,"changeRate":-0.000332,"amplitude":0.034862},"postHourTrading":{"tag":"盘后","latestPrice":752.25,"preClose":752.25,"latestTime":"19:36 EDT","volume":163697,"amount":123146499.652,"timestamp":1790638575697,"change":0,"changeRate":0,"amplitude":0.002991},"volumeRatio":1.7850653580744726,"impliedVol":0.378,"impliedVolPercentile":0.66},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1153528610","title":"异动解读｜再生元制药公司盘中下跌3.52%，报763.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153528610","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153528610?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:46","pubTimestamp":1790603193,"startTime":"0","endTime":"0","summary":"9月28日，再生元制药公司盘中下跌3.52%，报763.31美元/股，成交额5641.1万美元。再生元制药公司所在的生物科技行业中，个股中，Kodiak Sciences Inc.涨138.01%，Moderna, Inc.跌3.46%，吉利德科学跌0.35%，Lakewood-Amedex Biotherapeutics涨2.69%，安进涨0.57%。再生元制药公司于1988年在纽约州注册成立，是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物，核心业务覆盖多个治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127394018","title":"异动解读｜再生元制药盘中上涨3.05%，RBC称公司正考虑扩大与赛诺菲合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1127394018","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127394018?lang=zh_cn&edition=full","pubTime":"2026-09-03 00:58","pubTimestamp":1788368326,"startTime":"0","endTime":"0","summary":"9月2日，再生元制药盘中上涨3.05%，报848.935美元/股，成交额2.19亿美元。消息面上，RBC Capital Markets发布报告称，再生元可能将与赛诺菲的长期药物合作伙伴关系扩展至多款新免疫学药物。RBC指出，再生元可能寻求在全球范围内更均衡的利润分成安排，改变当前由赛诺菲先行承担大部分开发费用、再生元后续偿还的模式，不过财务收益短期内或难以显现。RBC维持对再生元\"与大盘持平\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元股价上扬，赛诺菲合作或迎新突破","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191130245","title":"异动解读｜再生元制药盘中上涨3.01%，RBC称公司正考虑扩大与赛诺菲合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1191130245","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191130245?lang=zh_cn&edition=full","pubTime":"2026-09-02 03:03","pubTimestamp":1788289401,"startTime":"0","endTime":"0","summary":"9月2日，再生元制药盘中上涨3.01%，报823.126美元/股，成交额3.03亿美元。消息面上，RBC Capital Markets发布报告称，再生元可能将与赛诺菲的长期药物合作伙伴关系扩展至多款新免疫学药物。目前合作仅涵盖Dupixent和Kevzara，双方均表示对重新谈判协议持开放态度。RBC指出，再生元可能寻求在全球范围内更均衡的利润分成，改变当前由赛诺菲先行承担大部分开发费用、再生元后续偿还的模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元盘中上涨，合作扩围预期升温","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元制药旗下Pasatru获欧洲药品管理局审评，全球申报在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105025052?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IBB","LU0289739699.SGD","LU2106854487.HKD","LU2089984988.USD","LU0058720904.USD","IBBQ","LU0823434740.USD","LU2362541273.HKD","TBXU","LU2237438978.USD","BK4585","LU0320765992.SGD","REGN","LU0823434583.USD","LU0114720955.EUR","LU0053666078.USD","LU0882574055.USD","LU1974910355.USD","BK4139","LU2468319806.SGD","LU0823416689.USD","LU0889565916.HKD","BBH","LU2023250504.SGD","LU2362541513.USD","LU1917777945.USD","LU2362540622.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元制药获FDA批准：Pasatru（Garetosmab-Grts）上市，治疗成人进行性骨化性纤维发育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188134905?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BBH","LU1974910355.USD","LU2362541273.HKD","BK4588","LU0114720955.EUR","LU2023250504.SGD","LU0823434740.USD","REGN","LU0823416689.USD","LU2468319806.SGD","LU0109394709.USD","LU0882574055.USD","LU1917777945.USD","IBB","LU2237438978.USD","BK4139","BK4585","TBXU","LU0053666078.USD","IBBQ","LU2089984988.USD","LU0889565916.HKD","LU2362541513.USD","LU0320765992.SGD","LU0823434583.USD","LU2106854487.HKD","LU2362540622.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170153585","title":"异动解读｜再生元制药公司盘中上涨3.44%，投行大幅上调目标价叠加生物科技板块强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1170153585","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170153585?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:55","pubTimestamp":1787147700,"startTime":"0","endTime":"0","summary":"8月19日，再生元制药公司盘中上涨3.44%，报840.05美元/股，成交额1.01亿美元。消息面上，Leerink Partners于8月17日将再生元目标价从641美元大幅上调至824美元，上调幅度达28.5%，维持市场表现评级。此前Bernstein亦小幅上调目标价至756美元。此外，生物科技板块当日整体走强，Moderna涨超116%，BioNTech涨近20%，板块联动亦提供上行动能。再生元制药公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物，核心业务覆盖多个治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194575176","title":"异动解读｜再生元制药盘中上涨3.01%，多重利好叠加提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1194575176","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194575176?lang=zh_cn&edition=full","pubTime":"2026-08-11 03:09","pubTimestamp":1786388968,"startTime":"0","endTime":"0","summary":"8月11日，再生元制药盘中上涨3.01%，报807.99美元/股，成交额3.31亿美元。消息面上，公司近期利好密集释放。8月6日，旗下药物Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌辅助治疗，填补该领域未满足医疗需求。此外，公司此前公布的第二季度业绩大幅超预期，调整后每股收益14.29美元，远超市场预期的10.26美元，营收42.91亿美元，同比增长17%，亦显著高于预期的38.16亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118060249","title":"再生元加拿大公司宣布Libtayo获加拿大卫生部批准用于特定类型癌症辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1118060249","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118060249?lang=zh_cn&edition=full","pubTime":"2026-08-06 23:49","pubTimestamp":1786031342,"startTime":"0","endTime":"0","summary":"（路透社消息）再生元加拿大公司（Regeneron Canada）近日宣布，其免疫药物Libtayo已获得加拿大卫生部（Health Canada）的批准，可用于高风险皮肤鳞状细胞癌（cutaneous squamous cell carcinoma）的辅助治疗。这一批准标志着该药物在癌症治疗领域迈出了重要一步，为高风险患者群体带来了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU2023250504.SGD","LU1917777945.USD","LU0114720955.EUR","REGN","LU0320765992.SGD","LU2362541273.HKD","LU2468319806.SGD","BBH","LU2362540622.SGD","LU0109394709.USD","LU2106854487.HKD","LU2362541513.USD","LU2089984988.USD","LU0289739699.SGD","LU0823416689.USD","LU0882574055.USD","LU2237438978.USD","BK4585","LU0053666078.USD","IBB","BK4139","LU0889565916.HKD","TBXU","BK4588","LU0058720904.USD","LU0823434740.USD","IBBQ","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101250335","title":"再生元加拿大公司：Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌的辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1101250335","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101250335?lang=zh_cn&edition=full","pubTime":"2026-08-06 23:31","pubTimestamp":1786030270,"startTime":"0","endTime":"0","summary":"再生元加拿大公司宣布，其药物Libtayo已获得加拿大卫生部的批准，用于高危皮肤鳞状细胞癌的辅助治疗。这一关键进展为高风险患者提供了新的治疗选择，填补了该领域未满足的医疗需求。Libtayo作为免疫疗法，通过激活人体免疫系统来对抗肿瘤，其安全性和有效性已在临床试验中得到验证。加拿大卫生部的批准基于对复发风险的显著降低数据，标志着再生元在肿瘤治疗领域的持续扩展。此次获批，不仅巩固了Libtayo在皮肤癌治疗中的地位，也为患者带来了更早干预的机会，有望改善预后并降低复发率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0320765992.SGD","LU0823434583.USD","LU2023250504.SGD","LU0823434740.USD","LU0109394709.USD","LU0889565916.HKD","BK4588","LU2468319806.SGD","LU0289739699.SGD","LU0882574055.USD","LU0114720955.EUR","LU2362541273.HKD","TBXU","BBH","BK4585","LU2089984988.USD","LU1917777945.USD","LU1974910355.USD","LU0823416689.USD","LU2362541513.USD","LU0058720904.USD","IBB","LU2362540622.SGD","BK4139","REGN","LU2106854487.HKD","LU0053666078.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185995984","title":"一周美股牛榜 | 微软上周飙升近22%，佳明涨近21%，亚马逊、墨式烧烤上涨17%，再生元制药涨超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185995984","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185995984?lang=zh_cn&edition=full","pubTime":"2026-08-03 10:22","pubTimestamp":1785723732,"startTime":"0","endTime":"0","summary":"佳明报告第二季度调整后每股收益为2.81美元，高于去年同期的2.17美元，也远超分析师预期的2.30美元。收入增长11%至20.2亿美元，超过华尔街预期的19.3亿美元。佳明预测2026年每股收益为10美元，高于此前估计的9.35美元。根据LSEG汇编的数据，截至6月30日的第二季度，亚马逊云计算部门AWS的收入增长37%，达到422亿美元，而分析师普遍预期为增长31.21%。再生元制药公司上涨16%，第二季度业绩大幅超出预期$再生元制药公司$ 本周上涨16%。","market":"us","thumbnail":"https://static.tigerbbs.com/591f197978533795137daedf87e7f110","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/591f197978533795137daedf87e7f110"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMG","MSFL","AMZY","AZYY","AMZD","AMZU","GRMN","MSFD","MSFY","AMZW","REGN","AMZN","MSFW","AMZP","CMGG","AMZZ","MSFU","MSFO","MSFX","MSFT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1187179484","title":"异动解读｜再生元制药公司盘中上涨3.09%，Q2财报大幅超预期带动股价延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1187179484","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187179484?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:24","pubTimestamp":1785525889,"startTime":"0","endTime":"0","summary":"8月1日，再生元制药公司盘中上涨3.09%，报761.175美元/股，成交额5.49亿美元。消息面上，公司此前公布的第二季度财报大幅超出市场预期，延续推动股价上行。数据显示，Q2营收达42.91亿美元，同比增长17%，显著高于市场预期的38.16亿美元；调整后每股收益为14.29美元，远超分析师一致预期的10.26美元，超出幅度达39.28%。值得注意的是，公司此前曾在SEC文件中预警Q2每股收益将减少约1美元，实际表现却大幅好于预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166410715","title":"异动解读 | 再生元制药盘中大涨5.79%，Q2财报及核心药物销售双双超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166410715","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166410715?lang=zh_cn&edition=full","pubTime":"2026-07-31 03:22","pubTimestamp":1785439356,"startTime":"0","endTime":"0","summary":"再生元制药公司今日盘中股价大涨5.79%，引发市场广泛关注。消息面上，再生元制药在盘前公布了第二季度财报，业绩大幅超出市场预期。数据显示，公司Q2营收达42.91亿美元，同比增长17%，显著高于市场预期的38.16亿美元；调整后每股收益为14.29美元，远超分析师预期的10.3美元，超出幅度达39.28%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139424257","title":"异动解读｜再生元制药公司盘中上涨3.19%，Q2财报大幅超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1139424257","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139424257?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:49","pubTimestamp":1785422980,"startTime":"0","endTime":"0","summary":"7月30日，再生元制药公司盘中上涨3.19%，报704.7美元/股，成交额2.4亿美元。消息面上，公司于盘前公布第二季度财报，业绩大幅超出市场预期。数据显示，Q2调整后每股收益为14.29美元，远超分析师一致预期的10.26美元，超出幅度达39.28%，较去年同期的12.89美元增长10.86%；营收达42.91亿美元，超出市场预期的38.16亿美元。值得注意的是，公司此前曾在SEC文件中预警Q2每股收益将减少约1美元，实际表现却大幅好于预期，推动股价快速上行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150899419","title":"赛诺菲预期研发支出将温和增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1150899419","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150899419?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:55","pubTimestamp":1785416128,"startTime":"0","endTime":"0","summary":"赛诺菲首席执行官Belen Garijo在分析师电话会议上表示，预计中期内公司的研发支出将呈现温和增长态势。同时，Garijo强调：“我们必须迎头赶上，并充分利用中国正在涌现的创新浪潮。”然而，他同时指出，赛诺菲在中国的战略可能不会完全复制其全球战略。此外，赛诺菲方面明确，与再生元制药公司的合作并非公司推进并购交易的障碍。一位赛诺菲高管还透露，预计Dupixent的专利保护期将持续到2031年3月之后。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","LU2468319806.SGD","LU2362541513.USD","IBBQ","BK4585","LU2362540622.SGD","BK4588","LU1974910355.USD","BK4139","LU2089984988.USD","TBXU","LU0823434740.USD","REGN","LU0320765992.SGD","LU0058720904.USD","LU0889565916.HKD","BBH","IBB","LU2362541273.HKD","LU0882574055.USD","LU2237438978.USD","LU0289739699.SGD","LU0823416689.USD","LU2106854487.HKD","LU0053666078.USD","LU2023250504.SGD","LU0109394709.USD","LU1917777945.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149696560","title":"再生元制药Q2调整后每股收益14.29美元，远超IBES预期10.3美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149696560","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149696560?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:50","pubTimestamp":1785408636,"startTime":"0","endTime":"0","summary":"再生元制药第二季度营收达到42.91亿美元，显著高于IBES预估的38.16亿美元。这一强劲表现不仅体现在营收端，更反映在盈利能力上——公司调整后的每股收益为14.29美元，远高于市场预期的10.3美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2362541273.HKD","LU0882574055.USD","LU0823434583.USD","LU0320765992.SGD","LU0114720955.EUR","LU2089984988.USD","BBH","LU2023250504.SGD","IBB","BK4585","LU1974910355.USD","LU0058720904.USD","LU0823416689.USD","LU0289739699.SGD","BK4588","LU1917777945.USD","LU2362541513.USD","LU0109394709.USD","LU2362540622.SGD","LU2468319806.SGD","BK4139","LU0823434740.USD","REGN","TBXU","IBBQ","LU0053666078.USD","LU2106854487.HKD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132894827","title":"异动解读｜再生元制药公司盘前上涨4.25%，Q2财报大幅超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1132894827","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132894827?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:36","pubTimestamp":1785407792,"startTime":"0","endTime":"0","summary":"7月30日，再生元制药公司盘前上涨4.25%，报725.5美元/股，成交额40.59万美元。消息面上，公司于盘前公布第二季度财报，业绩大幅超出市场预期。数据显示，公司Q2调整后每股收益为14.29美元，远超分析师一致预期的10.26美元，超出幅度达39.28%，较去年同期的12.89美元增长10.86%；营收达42.91亿美元，超出市场预期的38.16亿美元。此前公司曾在SEC文件中预警Q2每股收益将减少约1美元，实际表现却大幅好于预期，推动股价快速上行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再生元制药Q2财报大幅超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135699267","title":"异动解读｜再生元制药盘中上涨3.05%，生物科技板块集体走强叠加财报临近","url":"https://stock-news.laohu8.com/highlight/detail?id=1135699267","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135699267?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:38","pubTimestamp":1785249522,"startTime":"0","endTime":"0","summary":"7月27日，再生元制药盘中上涨3.05%，报690.79美元/股，成交额9666.98万美元。消息面上，生物科技板块当日集体走强，同行业安进涨5.32%、吉利德科学涨3.36%、艾伯维涨3.29%、阿尔尼拉姆制药涨3.18%、福泰制药涨2.58%，板块整体呈现资金流入态势。此外，公司将于7月30日盘前公布第二季度财报，市场或提前进行仓位调整。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148024164","title":"异动解读｜再生元制药盘中上涨3.08%，报676.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148024164","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148024164?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:33","pubTimestamp":1785162813,"startTime":"0","endTime":"0","summary":"7月27日，再生元制药盘中上涨3.08%，报676.22美元/股，成交额9646.43万美元。再生元制药所在的生物科技行业中，个股中，Forte BioSciences涨39.55%，Entera Bio涨93.66%，福泰制药涨1.82%，吉利德科学涨2.53%，艾伯维公司涨0.69%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116304977","title":"异动解读｜再生元制药盘中下跌3.28%，多家投行下调目标价叠加财报预警","url":"https://stock-news.laohu8.com/highlight/detail?id=1116304977","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116304977?lang=zh_cn&edition=full","pubTime":"2026-07-23 00:33","pubTimestamp":1784738021,"startTime":"0","endTime":"0","summary":"7月22日，再生元制药盘中下跌3.28%，报653.06美元/股，成交额1.23亿美元。消息面上，Cantor Fitzgerald于7月22日将再生元制药目标价从785美元下调至750美元，此前高盛也将目标价从968美元微调至965美元。近期HSBC更大幅将目标价从990美元削减至800美元。多家机构集中下调目标价，反映市场对公司前景的谨慎预期。此外，5月核心药物fianlimab联合疗法三期试验未达主要终点的阴影仍未完全消散，多重利空因素共振下股价承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125509855","title":"异动解读｜再生元制药盘前下跌3.2%，多家投行下调目标价叠加Q2业绩预警承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1125509855","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125509855?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:40","pubTimestamp":1784191203,"startTime":"0","endTime":"0","summary":"7月16日，再生元制药盘前下跌3.2%，报656.9美元/股。消息面上，近期多家投行密集下调公司目标价，叠加公司预告Q2每股收益将减少约1美元，市场情绪持续承压。此前公司提交SEC文件披露，预计Q2 GAAP及非GAAP每股摊薄收益将较预期减少约1美元，市场对7月30日即将发布的二季报表现存在担忧。此外，5月核心药物fianlimab三期试验未达主要终点的阴影仍未完全消散，多家机构此前已下调评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再生元制药盘前下跌3.2%，多家投行下调目标价叠加Q2业绩预警承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0575},{"period":"1month","weight":-0.0528},{"period":"3month","weight":0.2064},{"period":"6month","weight":-0.0322},{"period":"1year","weight":0.334},{"period":"ytd","weight":-0.0254}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.006953},{"month":7,"riseRate":0.666667,"avgChangeRate":0.057379},{"month":8,"riseRate":0.555556,"avgChangeRate":0.023569},{"month":9,"riseRate":0.444444,"avgChangeRate":0.021007},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}